MARKET NEWS

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal & Systemic Immune Responses in Non-Human Primates
BioDelivery Sciences International Announces ELYXYB is Now Available in the US for the Acute Treatment of Migraine
HiberCell Initiates its Phase 1a/b Clinical Trial in Patients With Advanced Solid Tumors
Cyclerion Therapeutics & Ariana Pharma Announce Artificial Intelligence-Driven Precision Medicine Collaboration
Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase 1 Clinical Trial
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus Vaccine Candidate

  FEATURED EDITORIAL

  COMPANY PROFILE

With over 70 years of proven experience, Aptar Pharma is the go-to drug delivery expert for pharma customers worldwide, providing innovative drug delivery systems, components and active material science solutions across the widest range of therapeutic areas and delivery routes including nasal, pulmonary, ophthalmic, dermal and injectables. Aptar Pharma Services provide early stage to commercialization support to accelerate and derisk the drug development journey. With a strong focus on innovation, Aptar Pharma is leading the way in developing connected devices to deliver digital healthcare solutions. With a global manufacturing footprint of 14 GMP sites, Aptar Pharma provides security-of-supply and local support to customers. Click here for more.

Alcami Video Spotlight

  EXCLUSIVE ONLINE CONTENT

CDMOs Need to be Prepared for the Revision of the EU-GMP-Annex 1

CDMOs Need to be Prepared for the Revision of the EU-GMP-Annex 1

Annex 1 of the EU-GMP-Guide Manufacture of Sterile Medicinal Products is considered the most important European regulatory standard for the manufacture of sterile pharmaceutical products. The current revision will have to….

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

TFF Pharmaceuticals, Inc. recently announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the company’s inhaled niclosamide product candidate completely….

Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to….

Hovione & Zerion Pharma Announce Strategic Partnership

Hovione & Zerion Pharma Announce Strategic Partnership

Hovione recently announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome, Zerion´s proprietary solubility enhancement….

Medigene & BioNTech Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer

Medigene & BioNTech Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer

Medigene AG and BioNTech SE recently announced they have entered a multi-target research collaboration to develop T cell receptor (TCR) based….

Enteris BioPharma Highlights Progress in Oral Feasibility Program

Enteris BioPharma Highlights Progress in Oral Feasibility Program

Enteris BioPharma, Inc. recently provided an update on its oral feasibility programs involving the company’s Peptelligence and ProPerma oral peptide and small….

After 25 Years, There is a CEO Transition at Hovione!

After 25 Years, There is a CEO Transition at Hovione!

Hovione recently announced the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 9 – Particle Design Technology
March 16 – Formulation Development